We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+17.58%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$2.97B
AUM Growth
+$703M
Cap. Flow
+$803M
Cap. Flow %
27.04%
Top 10 Hldgs %
34.36%
Holding
350
New
119
Increased
64
Reduced
60
Closed
59

Top Buys

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$25.3M
2
LLY icon
Eli Lilly
LLY
+$24.5M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$18.4M
4
XFOR icon
X4 Pharmaceuticals
XFOR
+$15.7M
5
MGNX icon
MacroGenics
MGNX
+$12.2M

Top Sells

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$21.4M
2
KALV
KalVista Pharmaceuticals
KALV
+$20.2M
3
BMY icon
Bristol-Myers Squibb
BMY
+$17.9M
4
CLDX icon
Celldex Therapeutics
CLDX
+$17.7M
5
PRTA icon
Prothena Corp
PRTA
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 22.28%
2 Consumer Staples 0.05%
3 Financials 0.03%
4 Industrials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BDTX icon
151
Black Diamond Therapeutics
BDTX
$96.8M
$3.73M 0.13%
153,941
-140,000
-48% -$3.78M
ONC
152
CALL
BeOne Medicines Ltd
ONC
$32.8B
$3.65M 0.12%
+10,500
New +$3.48M
KDMN
153
DELISTED
Kadmon Holdings, Inc.
KDMN
$3.64M 0.12%
936,615
– –
ALLK
154
DELISTED
Allakos
ALLK
$3.64M 0.12%
+31,700
New +$4M
SEEL
155
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$3.58M 0.12%
+187
New +$2.18M
BCAB icon
156
BioAtla
BCAB
$5.46M
$3.57M 0.12%
+1,403
New +$3.6M
SVRA icon
157
Savara
SVRA
$1.12B
$3.57M 0.12%
+1,714,366
New +$2.93M
WHWK
158
Whitehawk Therapeutics
WHWK
$190M
$3.42M 0.12%
176,740
+145,021
+457% +$3.34M
SRRK icon
159
Scholar Rock
SRRK
$5.67B
$3.4M 0.11%
67,059
-50,000
-43% -$2.77M
DBVT
160
DBV Technologies
DBVT
$799M
$3.39M 0.11%
32,273
-3,560
-10% -$189K
FOLD
161
DELISTED
Amicus Therapeutics
FOLD
$3.37M 0.11%
+341,500
New +$5.29M
TNGX icon
162
Tango Therapeutics
TNGX
$4.43B
$3.34M 0.11%
300,250
+150,738
+101% +$1.73M
ACHV icon
163
Achieve Life Sciences
ACHV
$659M
$3.29M 0.11%
284,151
– –
MRSN
164
CALL
DELISTED
Mersana Therapeutics
MRSN
$3.24M 0.11%
+8,000
New +$3.88M
ALPN
165
DELISTED
Alpine Immune Sciences Inc
ALPN
$3.23M 0.11%
304,739
+300,000
+6,330% +$3.74M
BLUE
166
CALL
DELISTED
bluebird bio
BLUE
$3.2M 0.11%
8,199
– –
SBBP
167
DELISTED
Strongbridge Biopharma plc.
SBBP
$3.2M 0.11%
1,160,450
-1,279,578
-52% -$3.86M
MORF
168
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$3.16M 0.11%
49,925
-466,838
-90% -$21.4M
QSI icon
169
Quantum-Si Incorporated
QSI
$155M
$3.1M 0.1%
+260,000
New +$3.14M
STRO icon
170
Sutro Biopharma
STRO
$401M
$3.08M 0.1%
13,536
-48,000
-78% -$11.4M
CASI
171
DELISTED
CASI Pharmaceuticals
CASI
$3.04M 0.1%
126,815
– –
TCRR
172
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$3.01M 0.1%
136,486
+15,000
+12% +$409K
CYTK icon
173
Cytokinetics
CYTK
$10.5B
$2.95M 0.1%
127,000
-100,000
-44% -$2.14M
GYRE icon
174
Gyre Therapeutics
GYRE
$641M
$2.93M 0.1%
+77,493
New +$3.54M
IMTX icon
175
Immatics
IMTX
$1.18B
$2.86M 0.1%
255,138
-382,956
-60% -$4.34M
5 6
7
8 9

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2021 Portfolio in Review

As of Q1 2021, Ikarian Capital held 350 positions worth $2.97B, up 31% from $2.27B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Ikarian Capital deployed $803M of net new capital in Q1 2021, opening 119 new positions and adding to 64 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 1,336,412 shares worth $4.57M.

By sector, the portfolio is most concentrated in Healthcare at 22% of assets, down from 24% a quarter earlier, followed by Consumer Staples and Financials.

On the sell side, the largest reduction was Morphic Holding, Inc. Common Stock, an estimated $21.4M trimmed.

  • Ikarian Capital's largest Q1 2021 buy was Odonate Therapeutics, Inc. Common Stock: 1,336,412 shares worth $4.57M.
  • Ikarian Capital added most to X4 Pharmaceuticals in Q1 2021, an estimated $15.7M increase.
  • Ikarian Capital's biggest Q1 2021 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $21.4M.
  • Ikarian Capital fully exited Bristol-Myers Squibb in Q1 2021, selling an estimated $17.9M.
  • Ikarian Capital's ten largest holdings make up 34% of its $2.97B portfolio in Q1 2021.
  • Ikarian Capital opened 119 new positions and closed 59 in Q1 2021.
  • Ikarian Capital's portfolio value rose 31% quarter-over-quarter to $2.97B.

Based on Ikarian Capital's 13F filing for Q1 2021, filed 17 May 2021.